Antioxidant ·Moderate evidence ·Reviewed May 2026
Unique antioxidant that works in both water and fat environments. Regenerates other antioxidants (vitamins C, E, glutathione, CoQ10). Powerful support for blood sugar and nerve health.
The bottom line
Evidence rating moderate. Most-documented uses: blood sugar support, nerve health, antioxidant regeneration. 18 sources indexed (1995–2024), with 31 interaction records on file.
Core mechanism
Cofactor for mitochondrial dehydrogenase complexes (pyruvate dehydrogenase, alpha-ketoglutarate dehydrogenase). Potent metal chelator. Regenerates glutathione, vitamin C, vitamin E, and CoQ10. Activates AMPK (improves glucose uptake). Scavenges ROS in both aqueous and lipid compartments.1,2
Take on empty stomach 30 min before meals; food reduces absorption by 30%9,1
Dosing protocol
R-ALA is the active stereoisomer; racemic ALA is more common. Take away from meals for absorption.9
Ranked by evidence and value.
Real-world pricing across three quality tiers. Assumes Alpha-Lipoic Acid.
Assumes about 300-600 mg/day. R-lipoic and stabilized specialty formats account for most premium pricing. Updated 2026-04-02.
How much you'd eat to match a supplemental dose.
A food-only match for common supplemental doses is not realistic.
Dose: 300-600 mg daily
Timing: Empty stomach if tolerated
Can lower glucose enough to matter when combined with other glucose-lowering agents.
Dose: 600 mg daily
Timing: Split morning and afternoon if needed
Most often used for neuropathy-focused protocols.
What to test, the optimal window inside the conventional range, and how long a response takes.
Alpha-lipoic acid (600 to 1200 mg per day) modestly lowers fasting glucose and HbA1c in type 2 diabetes; effects in non-diabetics are smaller.12,1
ALA also improves symptoms of diabetic peripheral neuropathy in RCTs. Direct serum ALA assays are research-only.
Alpha-Lipoic Acid is expected to modestly lower Hemoglobin A1c in type 2 diabetes, with effects that are typically small, dose-dependent, and clearest when HbA1c is elevated at baseline.1,2
No fasting required since HbA1c reflects roughly 3 months of average glucose. Conditions affecting red blood cell turnover (anemia, recent transfusion, hemoglobin variants) can distort the result. Retest no sooner than about 3 months apart.
Alpha-lipoic acid is an antioxidant that may improve how cells respond to insulin, which can translate into a modest lowering of fasting insulin over time. The evidence is emerging and mixed: some trials in people with insulin resistance or type 2 diabetes report small improvements, while others show little to no effect, so any benefit should be considered preliminary rather than established.17,1
Fasting insulin should be drawn after a true overnight fast (typically 8 to 12 hours, water only), and it is most useful when measured at the same time of day and in the same lab to keep assay variation low. Interpret it alongside fasting glucose rather than in isolation. Alpha-lipoic acid is often taken on an empty stomach or before meals, but do not change your dosing on the morning of a blood draw; keep conditions consistent. Most importantly, if you take diabetes medication or insulin, work with your clinician before and during use, because alpha-lipoic acid can add to glucose-lowering effects and raise the risk of hypoglycemia. Any dose adjustments should be medically supervised.
Where this appears in the symptom-to-supplement map, ranked by relevance.
Alpha-lipoic acid is an antioxidant that reduces oxidative nerve stress and has improved neuropathic symptoms, especially in diabetic peripheral neuropathy trials.2,5
Take on an empty stomach; the R-isomer is more bioactive than racemic mixtures.
Alpha-lipoic acid is a neuroprotective antioxidant that has reduced oral burning in several trials, likely by calming small-fiber nerve dysfunction in the tongue.1,2
Often trialed for 1 to 2 months. Results are inconsistent across studies, so view it as a reasonable first supplement to test rather than a guaranteed fix.
An antioxidant whose clearest evidence is for easing diabetic peripheral neuropathy symptoms, with weaker and mixed effects on glucose control itself.3,14
Most valued for neuropathy symptoms; monitor blood sugar since it may add to glucose-lowering effects, and manage diabetes with your clinician.
Alpha-lipoic acid is an antioxidant that reduces oxidative nerve stress and has its strongest evidence in neuropathic pain, with some study in radicular pain.3,1
May modestly lower blood sugar, so monitor if diabetic. Best evidence is for diabetic neuropathy, extrapolated to sciatica.
ALA is a mitochondrial antioxidant that may improve insulin-stimulated glucose disposal and reduce oxidative stress that contributes to insulin resistance.14,17
Best absorbed away from food, and its strongest clinical data is actually for diabetic neuropathy symptoms.
ALA is commonly used for peripheral nerve discomfort and diabetic neuropathy support.
Most relevant when neuropathy and blood-sugar issues overlap.
ALA supports insulin sensitivity and oxidative stress control in glucose dysregulation.17
More relevant when nerve symptoms coexist.
Its antioxidant action targets the oxidative nerve injury thought to drive platinum and taxane induced neuropathy.2,5
A large RCT for prevention was negative, so frame as supportive at best. Coordinate with oncology, as antioxidants may interfere with some chemotherapy.
Alpha-lipoic acid may improve glucose uptake and insulin sensitivity, though its role in dampening post-meal glucose swings is not well established.1,2
Can lower blood glucose, so monitor for symptoms; supportive only and not a treatment, and see a clinician for recurrent crashes.
Alpha-Lipoic Acid is a mitochondrial cofactor and antioxidant that may theoretically offset oxidative stress proposed to contribute to ME/CFS fatigue.1,2
Direct ME/CFS data are very limited; monitor blood sugar if you take diabetes medication and confirm use with your clinician.
As an antioxidant with nerve-supportive effects, alpha-lipoic acid has been trialed for post-viral and idiopathic smell loss to aid sensory nerve recovery.
Human evidence for smell recovery is limited and mixed. Best viewed as an adjunct alongside smell training and clinician evaluation.
Its antioxidant action and improved glucose uptake can ease the oxidative and insulin-resistance load of the cluster.12,11
Helpful as a supporting antioxidant rather than a primary fix.
Evidence-based stacks that include it, with the exact dose and timing each one uses.
ALA improves insulin sensitivity and reduces fasting glucose in T2D; also addresses diabetic peripheral neuropathy.17,12
Alpha-Lipoic Acid is a mitochondrial cofactor and antioxidant that can help regenerate other antioxidants such as glutathione and vitamins C and E, and may support redox balance. Longevity-specific human data are limited and much of the supporting evidence is from animal models.1,2
Alpha-Lipoic Acid serves as a cofactor for the pyruvate dehydrogenase complex that feeds the citric acid cycle, and it acts as an amphiphilic antioxidant that can help regenerate other endogenous antioxidants. Absorption is reduced when taken with food, so it is generally taken on an empty stomach.1,2
Alpha-Lipoic Acid is both water and fat soluble, so it can scavenge radicals in aqueous and lipid compartments. In laboratory and animal studies it also helps regenerate other antioxidants such as glutathione and vitamin C, though the strength of this recycling effect at typical oral doses in humans is less well established.18,2
Alpha-lipoic acid has the most direct supplement evidence for diabetic polyneuropathy symptom support, likely through oxidative stress and glucose-related nerve pathways. Monitor glucose if using diabetes medication.1,4
Both support glutathione recycling. ALA regenerates glutathione from its oxidized form, while NAC provides the cysteine precursor for new glutathione synthesis.
Recommendation: Powerful antioxidant combination for glutathione support and heavy metal chelation.
ALA regenerates vitamin C from its oxidized form (dehydroascorbate) back to ascorbate.
Recommendation: Taking together creates an antioxidant recycling network: ALA → regenerates C → regenerates E.
ALA chelates metals including iron. May reduce iron absorption or redistribute iron stores.
Recommendation: Separate by 2+ hours. Avoid high-dose ALA if you have iron deficiency.
Alpha-lipoic acid competes with biotin (B7) for the SMVT transporter in the gut, potentially reducing biotin absorption.
Recommendation: Separate ALA and biotin by at least 2 hours. If taking ALA long-term, consider extra biotin supplementation.
Pantothenate (B5) also uses the SMVT transporter and may compete with alpha-lipoic acid for absorption.
Recommendation: Separate by 2 hours if taking high doses of either. At typical supplement doses, competition is minimal.
Both support mitochondrial function. CoQ10 is essential for the electron transport chain; ALA is a cofactor for mitochondrial dehydrogenases.
Recommendation: Combine for comprehensive mitochondrial support, especially for cardiovascular and neurological health.
Both improve insulin sensitivity through AMPK activation. ALA also supports glucose uptake via GLUT4 translocation.
Recommendation: Combine for enhanced metabolic support. Monitor blood glucose if combining with diabetes medications.
ALA regenerates vitamin C from its oxidized form (dehydroascorbate) back to ascorbate.
Recommendation: Taking together creates an antioxidant recycling network: ALA → regenerates C → regenerates E.
ALA chelates metals including iron bisglycinate. May reduce iron bisglycinate absorption or redistribute iron bisglycinate stores.
Recommendation: Separate by 2+ hours. Avoid high-dose ALA if you have iron bisglycinate deficiency.
Both support mitochondrial function. CoQ10 is essential for the electron transport chain; ALA is a cofactor for mitochondrial dehydrogenases.
Recommendation: Combine for comprehensive mitochondrial support, especially for cardiovascular and neurological health.
Both improve insulin sensitivity through AMPK activation. ALA also supports glucose uptake via GLUT4 translocation.
Recommendation: Combine for enhanced metabolic support. Monitor blood glucose if combining with diabetes medications.
Both improve mitochondrial function in aging models; the classic Hagen and Ames protocol pairs them for cellular energy support.
Recommendation: Combine for age-related fatigue or mitochondrial support. Standard doses: ALCAR 1 to 2 g, ALA 200 to 600 mg per day.
Numbered references. Citations throughout the page link here.
Sharifi-Zahabi E, Abdollahzad H. Alpha Lipoic Acid Supplementation and Iron Homeostasis: A Comprehensive Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials. International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition. 2024
Meta-analysis showed ALA reduced total symptom scores by -2.26 in diabetic neuropathy, with both oral and IV administration showing significant improvements.
Alpha-lipoic acid demonstrated significant effectiveness in reducing neuropathic pain scores in both type 1 and type 2 diabetic patients compared to placebo in pooled analysis.
Among various micronutrients evaluated, alpha-lipoic acid was associated with reduced cardiovascular risk markers in this comprehensive systematic review of micronutrient supplementation trials.
Abubaker SA, Alonazy AM, Abdulrahman A. Effect of Alpha-Lipoic Acid in the Treatment of Diabetic Neuropathy: A Systematic Review. Cureus. 2022
Dong L, Yang F, Li J et al.. Effect of oral alpha-lipoic acid (ALA) on sperm parameters: a systematic review and meta-analysis. Basic and clinical andrology. 2022
Di Tucci C, Galati G, Mattei G et al.. The role of alpha lipoic acid in female and male infertility: a systematic review. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology. 2021
Sheikholeslami S, Khodaverdian S, Dorri-Giv M et al.. The radioprotective effects of alpha-lipoic acid on radiotherapy-induced toxicities: A systematic review. International immunopharmacology. 2021
ALA reduced BMI by 0.38 kg/m2 and body weight by 0.69 kg; linear dose-response at supplementation >600 mg/day.
Erickson N, Zafron M, Harding SV et al.. Evaluating the Lipid-Lowering Effects of α-lipoic Acid Supplementation: A Systematic Review. Journal of dietary supplements. 2020
de Sousa CNS, da Silva Leite CMG, da Silva Medeiros I et al.. Alpha-lipoic acid in the treatment of psychiatric and neurological disorders: a systematic review. Metabolic brain disease. 2019
ALA administration improved glucose homeostasis parameters and lipid profiles in patients with metabolic diseases.
Namazi N, Larijani B, Azadbakht L. Alpha-lipoic acid supplement in obesity treatment: A systematic review and meta-analysis of clinical trials. Clinical nutrition (Edinburgh, Scotland). 2018
ALA activates AMPK in skeletal muscle, increases fatty acid oxidation, and improves insulin sensitivity via reduced triglyceride accumulation.
Lipoic acid quenches ROS, chelates metal ions, and regenerates other antioxidants (vitamins C, E, glutathione) in both aqueous and lipid compartments.
This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.
Use this with your stack
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.
NutriStack